Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers

Single-dose administration of sugammadex 16, 20, or 32 mg kg−1 in combination with rocuronium 1.2 mg kg−1 or vecuronium 0.1 mg kg−1 was well tolerated with no clinical evidence of residual neuromuscular block, confirming that these combinations can safely be administered simultaneously to non-anaesthetized subjects. Rocuronium and vecuronium plasma concentrations decreased faster than those of sugammadex, reducing the theoretical risk of neuromuscular block developing over time.